Apart from a few subtype-specific genetic alterations, pituitary neuroendocrine tumours (PitNETs) exhibit a limited number of recurrent genetic alterations, emphasising the pivotal role of epigenetic dysregulation in their pathogenesis. DNA methylation has been widely investigated in PitNETs and has been associated with tumour subtypes, tumour biology and clinical outcome. Most studies used methodologies that cannot distinguish between methylation and active demethylation. DNA methylation is a dynamic and reversible process, governed by a tightly regulated cycle involving 5-methylcytosine and its oxidised derivatives - particularly 5-hydroxymethylcytosine - which have opposing effects on gene regulation. Failure to resolve these cytosine modifications may therefore obscure biologically relevant mechanisms and may contribute to inconsistent findings across studies. This mini-review critically examines the DNA methylation-demethylation cycle in PitNETs, discusses the challenges of accurately detecting cytosine modifications and summarises the emerging evidence linking altered demethylation dynamics to tumour differentiation, proliferation and aggressiveness. We also highlight the therapeutic relevance of targeting epigenetic regulators, such as DNA methyltransferases, TET enzymes and associated cofactors, and review data supporting both traditional epigenetic drugs and repurposed agents. Finally, we discuss future perspectives, including the potential of liquid biopsy-based methylation profiling and advanced sequencing technologies to improve PitNET classification, prognostication, and therapeutic stratification in the near future.
Szabó et al. (Tue,) studied this question.